Eligen B12™ is the only oral product clinically proven to normalize B12 levels without painful and inconvenient B12 injections. Eligen B12™ uses an advanced patented pharmaceutical carrier technology to optimize B12 absorption by chaperoning B12 directly into the bloodstream within 30 minutes, offering the following benefits:
- PREVENTS serious B12 deficiency, which is directly associated with irreversible nerve damage, early dementia, neurological changes, depression and anemia.
- OPTIMIZES B12 absorption for patients receiving B12 injections, or those taking inferior B12 nutritional supplements, especially individuals lacking intrinsic factor, or those who have had gastric surgeries.
- MAINTAINS consistent long-term and predictable healthy B12 blood levels with a single daily dose since there is no variability caused by monthly or missed injections and is superior to over-the-counter B12 supplements with erratic absorption properties and no clinical substantiation.
- PROTECTS patients taking chronic-use medicationsthat are known to cause serious B12 deficiency, including metformin (Glucophage), proton-pump inhibitors (Prevacid, Prilosec, Aciphex) and H2 antagonists (Zantac, Nexium, Tagamet).
Eligen B12™ is available as a tablet the size of a baby aspirin, and is available at amazon.com, lifeextensions.com and eligenb12com. The Company encourages patients (or caretakers of patients) who are currently taking intra-muscular B12 injections to speak to their health care provider about Eligen B12, and to view customer testimonials available at amazon.com and eligenb12.com.
ABOUT ELIGEN® TECHNOLOGY
Emisphere is a drug delivery company that utilizes its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partners with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, please visit the Company's website at www.emisphere.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development activities and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the Company's business development activities. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including, but not limited to, the sufficiency of
Source: Emisphere Technologies, Inc.